Sutro Biopharma, Inc. (STRO) News

Sutro Biopharma, Inc. (STRO): $7.11

-0.24 (-3.27%)

POWR Rating

Component Grades













Filter STRO News Items

STRO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

STRO News Highlights

  • For STRO, its 30 day story count is now at 4.
  • Over the past 21 days, the trend for STRO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • PFS are the most mentioned tickers in articles about STRO.

Latest STRO News From Around the Web

Below are the latest news stories about SUTRO BIOPHARMA INC that investors may wish to consider to help them evaluate STRO as an investment opportunity.

Are Investors Undervaluing Sutro Biopharma, Inc. (NASDAQ:STRO) By 46%?

In this article we are going to estimate the intrinsic value of Sutro Biopharma, Inc. ( NASDAQ:STRO ) by estimating the...

Yahoo | January 27, 2023

Sutro Biopharma Posts Updated Data From Ovarian Cancer Candidate

Sutro Biopharma Inc (NASDAQ: STRO) announced results from a Phase 1 dose-expansion study of STRO-002 (luvelta) and interim safety data from exploratory cohort C of advanced ovarian cancer treated at the higher dose of luvelta (5.2mg/kg), along with prophylactic pegfilgrastim. Results demonstrated that luvelta provided substantial clinical benefit, with a 37.5% overall response rate (ORR), a median duration of response (median DOR) of 5.5 months, and median progression-free survival (median PFS)

Yahoo | January 10, 2023

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer

- Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6 months at the higher starting dose of 5.2mg/kg - - Meaningful clinical benefit was observed in FolRα-selected patients, defined as TPS>25%, which is potentially 80% of the advanced ovarian cancer patient population - - Safety profile is generally consistent with prior data with asymptom

Yahoo | January 9, 2023

With 74% ownership of the shares, Sutro Biopharma, Inc. (NASDAQ:STRO) is heavily dominated by institutional owners

If you want to know who really controls Sutro Biopharma, Inc. ( NASDAQ:STRO ), then you'll have to look at the makeup...

Yahoo | January 6, 2023

Can you now get a good deal on Sutro Biopharma Inc.’s shares?

In Tuesday’s session, Sutro Biopharma Inc. (NASDAQ:STRO) marked $8.02 per share, down from $8.08 in the previous session. While Sutro Biopharma Inc. has underperformed by -0.74%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, STRO fell by -46.10%, with highs and lows ranging from $15.67 to […]

US Post News | January 4, 2023

Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA. The presentation will be accessible through the News & Ev

Yahoo | January 4, 2023

Is Sutro Biopharma Inc. (NASDAQ: STRO) A Suitable Stock For New Investors Now?

Sutro Biopharma Inc. (NASDAQ:STRO) price on Friday, December 23, fall -2.28% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $6.87. A look at the stock’s price movement, the close in the last trading session was $7.03, moving within a range at $6.665 and $7.13. The beta value … Is Sutro Biopharma Inc. (NASDAQ: STRO) A Suitable Stock For New Investors Now? Read More »

Stocks Register | December 24, 2022

Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer

- Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET - SOUTH SAN FRANCISCO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it will host a conference call and webcast to present data from its Phase 1 dose-expansion trial and a registrational path forward for STRO-002, an ADC

Yahoo | December 21, 2022

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract

- New Agreement Provides Vaxcyte Access to Expanded Rights to Develop and Manufacture Cell-Free Extract, a Key Component of Vaxcyte's Vaccine Candidates - - Sutro to Receive $22.5 Million in Upfront Payments and is Eligible for Up to an Additional $135 Million Pending Option Exercise and from Other Milestones - SOUTH SAN FRANCISCO, Calif. and SAN CARLOS, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro) (NASDAQ: STRO) and Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) today jointly

Yahoo | December 20, 2022

Investors in Sutro Biopharma (NASDAQ:STRO) have unfortunately lost 54% over the last year

While it may not be enough for some shareholders, we think it is good to see the Sutro Biopharma, Inc. ( NASDAQ:STRO...

Yahoo | December 17, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5359 seconds.